What is Semax and why does its sequence matter for identity analysis?
Semax is a synthetic regulatory peptide derived from the ACTH(4-10) fragment, extended with a C-terminal Pro-Gly-Pro motif that is characteristic of the molecule and relevant to analytical identity work. Because it is a defined short-chain peptide of known composition, its theoretical monoisotopic and average molecular masses can be calculated directly from the sequence and used as the reference value against which mass spectrometric results are compared. Identity analysis therefore begins with the documented target sequence: the amino acid composition determines the expected molecular weight, the theoretical amino acid ratios used in composition assays, and the fragmentation pattern expected under tandem MS. Literature describing Semax as a synthetic ACTH(4-10) analogue and its use in experimental neuroscience models confirms the sequence identity and structural class that a characterisation programme must reproduce. From an analytical standpoint, the practical questions are whether the supplied material matches this defined structure, whether deletion or insertion sequences (missing or extra residues) are present, and whether side-reaction products from synthesis are detectable. Establishing the reference sequence and its derived analytical constants up front makes every downstream method — HPLC retention behaviour, exact-mass confirmation, and impurity assignment — interpretable against a fixed target. Documentation of the intended sequence, one-letter and three-letter notation, molecular formula and calculated masses on the COA lets an independent researcher recompute the expected values and verify that the reported identity data are internally consistent. This is the difference between a label claim and a traceable, chemically-verified identity.
How is Semax identity confirmed by mass spectrometry?
Electrospray ionisation mass spectrometry (ESI-MS) is the primary tool for confirming Semax molecular-weight identity. In positive-ion mode a short peptide typically produces singly and multiply charged species; deconvolution of these m/z values yields an observed neutral mass that is compared to the mass calculated from the documented sequence. Agreement within a small mass tolerance (commonly a fraction of a Dalton for high-resolution instruments) supports identity, while systematic mass shifts can indicate oxidation, deletion sequences, incomplete deprotection or counterion adducts. For unambiguous confirmation beyond intact mass, tandem MS (MS/MS) fragments the peptide backbone to generate b- and y-ion series; matching the observed fragment ladder to the theoretical fragmentation of the target sequence confirms not just the total mass but the residue order. This sequence-level verification distinguishes Semax from isobaric or near-isobaric impurities that share a similar mass but differ in arrangement. Reported MS fields on a COA should include the ionisation mode, observed versus theoretical mass, charge states considered, and instrument resolution class. When mass spectrometry is combined with orthogonal chromatography (discussed next), the two techniques together provide the standard identity-plus-purity picture expected for a characterised research peptide. Published Semax studies consistently treat the compound as a defined synthetic analogue, reinforcing that a rigorous identity assay must reproduce the exact target mass and, ideally, the sequence-confirming fragment pattern before a lot is considered characterised for research documentation.
How is chromatographic purity of Semax measured by HPLC?
Reversed-phase high-performance liquid chromatography (RP-HPLC) is the standard method for quantifying the chromatographic purity of Semax. The peptide is separated on a C18 stationary phase using a water/acetonitrile gradient with an ion-pairing modifier such as trifluoroacetic acid, and detection is typically by UV at 210–220 nm where the peptide bond absorbs. Purity is expressed as the percentage of the total integrated peak area attributable to the main Semax peak, with related substances appearing as resolved earlier- or later-eluting peaks. A robust purity method must demonstrate adequate resolution between the main peak and its nearest impurities, a stable baseline, and reproducible retention. Peak-purity assessment — for example using photodiode-array spectral comparison across a peak — helps confirm that a single peak is not hiding a co-eluting impurity, which is why 'peak purity HPLC' is a meaningful field on analytical reports. General guidance on purity profiling of peptide drugs emphasises that a single technique is insufficient and that chromatographic area-percent purity should be interpreted alongside identity and related-substance data. A COA should record the column chemistry, gradient, detection wavelength, main-peak area percent, and the acceptance threshold applied to the lot. Reporting the method conditions allows an independent laboratory to reproduce the separation and confirm that the stated purity value reflects a validated, resolving method rather than an under-resolved chromatogram that overstates purity.
What impurities, counterions and water content affect reported purity?
Chromatographic area-percent purity is only part of the quantitative picture for Semax. Synthetic peptides carry non-peptide mass in the form of counterions and residual water, so the reported HPLC purity and the actual net peptide content of a vial can differ substantially. Trifluoroacetate (TFA) is commonly associated with peptides purified using TFA-containing mobile phases, and its presence contributes mass that is not part of the peptide; documenting counterion identity and, where measured, counterion content clarifies what fraction of the weighed powder is peptide. Water content, determined by Karl Fischer titration, similarly accounts for hygroscopically bound moisture in a lyophilised solid. Related-substance analysis characterises process- and degradation-derived impurities — deletion sequences, oxidation products and aggregates — that RP-HPLC resolves as distinct peaks. Purity profiling guidance for peptide drugs frames these as complementary measurements: chromatographic purity, identity, related substances, counterion and water content together define the material. A complete COA therefore separates 'HPLC purity (area %)' from 'net peptide content', because a lot can be 98% chromatographically pure yet contain a lower percentage of peptide by mass once salt and water are subtracted. Understanding this distinction lets a researcher normalise experimental quantities to actual peptide mass and compare lots on a consistent basis rather than being misled by a single high area-percent figure.
How are Semax stability and batch documentation recorded for research use?
Beyond a single point-in-time identity and purity result, a characterisation programme documents stability-indicating information and batch traceability. Stability considerations for a lyophilised peptide include sensitivity to moisture, oxidation of susceptible residues, and physical changes on storage; a stability-indicating HPLC method is one able to resolve degradation products from the main peak so that any change in the impurity profile over time is detectable. Storage conditions (typically cold, protected from light and moisture) and reconstitution-solution stability are recorded so that the analytical values on the COA can be linked to defined handling assumptions. Batch documentation ties these results to a unique lot identifier: the COA should carry the lot number, manufacturing or analysis date, the analytical methods and their acceptance criteria, and the measured results for identity, purity, related substances, counterion and water content. Lot-release testing applies predefined acceptance criteria so that each batch is evaluated against the same standard, and traceability documentation links the certificate to the specific material a researcher receives. This documentation framework — identity confirmation, quantitative purity, impurity profiling, and stability context under a controlled lot record — is what distinguishes a characterised research material from an uncharacterised one. It is a chemistry-and-records exercise, entirely separate from any question of biological activity, and it is the basis on which a researcher can reproduce and audit the analytical claims made about a Semax lot.
Order Semax with documentation
If this guide helped you evaluate Semax for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Semax card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What does HPLC purity mean on a Semax certificate of analysis?
It is the percentage of total UV peak area attributed to the main Semax peak in a reversed-phase HPLC run. It reflects chromatographic purity relative to detectable related substances but does not by itself account for counterion salt or water, which are reported separately as net peptide content.
How is Semax identity distinguished from a similar peptide?
Intact-mass ESI-MS compares the observed deconvoluted mass to the mass calculated from the documented sequence. Tandem MS then fragments the backbone to confirm residue order via b- and y-ions, distinguishing Semax from isobaric impurities that share a mass but differ in sequence.
Why can net peptide content be lower than HPLC purity?
HPLC area percent measures purity among detectable peptide-related peaks, while net peptide content subtracts non-peptide mass such as counterions (e.g. TFA) and residual water measured by Karl Fischer. A lot can be high in chromatographic purity yet contain less peptide by total mass.
What is peak purity assessment in HPLC?
Peak purity assessment uses photodiode-array spectral comparison across a chromatographic peak to check that the spectrum is consistent throughout, indicating a single component rather than a hidden co-eluting impurity. It supports, but does not replace, orthogonal mass spectrometric identity confirmation.
What analytical fields should a Semax batch report contain?
A complete report lists lot number and date, sequence and calculated mass, HPLC method conditions and area-percent purity, MS identity results, related-substance data, counterion and Karl Fischer water content, plus storage conditions and the acceptance criteria applied at lot release.
References
- DOI:10.4172/1948-593x.s6-003 — Purity profiling of Peptide Drugs — Journal of Bioanalysis & Biomedicine — 2012
- DOI:10.1007/s10517-025-06501-z — The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons — Bulletin of Experimental Biology and Medicine — 2025
- DOI:10.1021/acschemneuro.1c00707 — Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models — ACS Chemical Neuroscience — 2022
- DOI:10.18097/bmcrm00033 — The Effect of New Synthetic Analogs of Semax Peptide Preparation on AMPA-Receptors in Purkinje Neurons of Cerebellar Rats — Biomedical Chemistry: Research and Methods — 2018
- DOI:10.1186/1471-2164-15-228 — The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis — BMC Genomics — 2014
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
